⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2024

Figure S7 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Daniel Peters Lena M. Kranz David Eisel Mustafa Diken Sebastian Kreiter Özlem Türeci Uğur Şahin Mathias Vormehr

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Gating strategy for antigen-specific CD8⁺ T cells, Tregs, and NK cells displayed in Figure 6.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peters et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efed91 https://doi.org/10.1158/2326-6066.27142698

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024
2Figure S6 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024
3Figure S9 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024
4Figure S8 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024
5Figure S11 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024
6Figure S10 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024
7Figure S3 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024
8Figure S4 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity2024